{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:28:17Z","timestamp":1778279297486,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejps.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T19:46:46Z","timestamp":1465415206000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Improving drug safety with a systems pharmacology approach"],"prefix":"10.1016","volume":"94","author":[{"given":"Peter","family":"Schotland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Bojunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Zien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam Nadine","family":"Trame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Lesko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.06.009_bb0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2016.06.009_bb0010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14656566.2013.783568","article-title":"Valdecoxib: the rise and fall of a COX-2 inhibitor","volume":"14","author":"Atukorala","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2016.06.009_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2016.06.009_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejps.2016.06.009_bb0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2016.06.009_bb0030","series-title":"FDA Adverse Event Reporting System (FAERS)","author":"Center for Drug Evaluation and Research","year":"2016"},{"key":"10.1016\/j.ejps.2016.06.009_bb0035","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1136\/amiajnl-2013-002512","article-title":"Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties","volume":"21","author":"Cheng","year":"2014","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.ejps.2016.06.009_bb0040","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/ci4000079","article-title":"Adverse drug events: database construction and in silico prediction","volume":"53","author":"Cheng","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejps.2016.06.009_bb0045","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1039\/c3mb25309k","article-title":"Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs)","volume":"9","author":"Cheng","year":"2013","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.ejps.2016.06.009_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1744-313X.2011.01011.x","article-title":"A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"38","author":"Cristallo","year":"2011","journal-title":"Int. J. Immunogenet."},{"issue":"41","key":"10.1016\/j.ejps.2016.06.009_bb0055","first-page":"192","article-title":"Drug-related morbidity and mortality: updating the cost-of-illness model","volume":"1996","author":"Ernst","year":"2001","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ejps.2016.06.009_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/14622416.9.1.35","article-title":"Pathway analysis tools and toxicogenomics reference databases for risk assessment","volume":"9","author":"Ganter","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejps.2016.06.009_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00002018-200730020-00004","article-title":"Potential use of data-mining algorithms for the detection of \u2018surprise\u2019 adverse drug reactions","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf. Int. J. Med. Toxicol. Drug Exp."},{"key":"10.1016\/j.ejps.2016.06.009_bb0070","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"issue":"514068","key":"10.1016\/j.ejps.2016.06.009_bb0075","article-title":"In silico risk assessment of HLA-A*02:06-associated Stevens-Johnson syndrome and toxic epidermal necrolysis caused by cold medicine ingredients","volume":"2013","author":"Isogai","year":"2013","journal-title":"J. Toxicol."},{"key":"10.1016\/j.ejps.2016.06.009_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/jhg.2013.37","article-title":"Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury","author":"Kaniwa","year":"2013","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejps.2016.06.009_bb0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/msb.2013.10","article-title":"Systematic identification of proteins that elicit drug side effects","volume":"9","author":"Kuhn","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.ejps.2016.06.009_bb0090","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejps.2016.06.009_bb0095","series-title":"Statistical Brief #109","first-page":"1","article-title":"Medication-related adverse outcomes in U.S. hospitals and emergency departments","author":"Lucado","year":"2011"},{"key":"10.1016\/j.ejps.2016.06.009_bb0100","first-page":"161","article-title":"Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy","volume":"142\u2013160","author":"Mockenhaupt","year":"2009","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG 7"},{"key":"10.1016\/j.ejps.2016.06.009_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejps.2016.06.009_bb0110","series-title":"ISMP Quarter Watch, May 7","author":"Moore","year":"2014"},{"key":"10.1016\/j.ejps.2016.06.009_bb0115","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","article-title":"Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity","volume":"26","author":"Norcross","year":"2012","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.ejps.2016.06.009_bb0120","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jaci.2010.11.046","article-title":"Drug hypersensitivity: pharmacogenetics and clinical syndromes","volume":"127","author":"Phillips","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2016.06.009_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1744-313X.2011.01061.x","article-title":"HLA alleles and drug hypersensitivity reactions","volume":"39","author":"Profaizer","year":"2012","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.ejps.2016.06.009_bb0130","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejps.2016.06.009_bb0135","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1475-6773.2011.01269.x","article-title":"Adverse drug events in U.S. adult ambulatory medical care","volume":"46","author":"Sarkar","year":"2011","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.ejps.2016.06.009_bb0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/pds.1323","article-title":"Data mining for signals in spontaneous reporting databases: proceed with caution","volume":"16","author":"Stephenson","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2016.06.009_bb0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf. Int. J. Med. Toxicol. Drug Exp."},{"key":"10.1016\/j.ejps.2016.06.009_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/amiajnl-2011-000214","article-title":"A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports","volume":"19","author":"Tatonetti","year":"2012","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.ejps.2016.06.009_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2016.06.009_bb0165","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejps.2016.06.009_bb0170","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2217\/bmm.15.81","article-title":"Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science","volume":"9","author":"Zhang","year":"2015","journal-title":"Biomark. Med"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T13:25:06Z","timestamp":1582550706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716302238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":33,"alternative-id":["S0928098716302238"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.06.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving drug safety with a systems pharmacology approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}